Hematologic Malignancies – XPOVIO (selinexor)

Solid Tumor Malignancies – Selinexor

Additional Oncology Programs – Eltanexor

Area of TherapyPhase IPhase IIPhase III
Myelodysplastic syndromes (alone or in combo with hypomethylating agents) | KCP-8602-801

Rights : Drug: Eltanexor / Combination study expected to start in 2020.

Phase I
Phase II
Phase III
Ongoing

Coming soon

Partnerships

antegene-logo

Antegene licensed rights to selinexor, eltanexor, verdinexor, and KPT-9274 in China, South Korea, Australia and additional Asia Pacific markets, excluding Japan.

Anivive holds exclusive worldwide rights to research, develop, and commercialize verdinexor only for the treatment of cancer in companion animals